Table 1

Baseline Characteristics of the PATH-CHF Study Group

CharacteristicRandomized toBiventricular Stimulation(n = 24)Randomized toUniventricular Stimulation(n = 17)All Enrolled Patients*(n = 42)
Age (yrs)59 ± 760 ± 560 ± 7
Gender (men/women)11/1310/721/21
Cause of heart failure
 Coronary artery disease10 (42%)1 (6%)12 (29%)
 Nonischemic dilated cardiomyopathy14 (58%)16 (94%)30 (71%)
New York Heart Association Functional class (III/IV)21/314/336/6
Electrocardiographic measurements
 Rest heart rate (beats/min)77 ± 1680 ± 1378 ± 15
 PR interval (ms)190 ± 34207 ± 30196 ± 33
 QRS duration (ms)174 ± 30178 ± 34175 ± 32
 Left bundle branch block21 (87%)17 (100%)39 (93%)
 Right bundle branch block3 (13%)03 (7%)
Echocardiographic measurements
 LVEF (%)21 ± 620 ± 721 ± 7
 LVEDD (mm)71 ± 1075 ± 1373 ± 11
 LVESD (mm)62 ± 968 ± 1464 ± 12
Medication
 ACE inhibitor (captopril) or Digitalis (digoxin)23 (96%)17 (100%)40 (95%)
 Vasodilators or nitrates17 (71%)12 (71%)29 (69%)
 Beta-blockers (metoprolol)§17 (71%)11 (65%)28 (67%)
 Amiodarone@01227 (29%)6 (35%)13 (30%)

ACE = angiotensin-converting enzyme; LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter.

  • * One enrolled patient was not randomized.

  • Patient with aortic stenosis excluded.

  • Dosage 98 ± 50 mg/day.

  • § Dosage 40 ± 20 mg/day.

  • @0122 Dosage 246 ± 88 mg/day. Data are presented as the mean value ± SD or number (%) of patients.